FDA Lifts Clinical Hold On Inovio's COVID-19 Vaccine Trial

The FDA has lifted a partial clinical hold on a late-stage trial of Inovio Pharmaceuticals Inc's INO COVID-19 vaccine in the U.S.
Inovio said it now has the authorization to proceed with the trial in the U.S. after 14 months.
Last year in September, the FDA put the final-stage trial on hold. It sought more information, including details on a delivery device used to inject genetic material into cells.
Inovio is partnering with Advaccine Biopharmaceuticals Suzhou Co Ltd to conduct the INNOVATE Phase 3 segment in the Americas, Asia, and Africa.
The Phase 3 segment of INNOVATE will evaluate the efficacy of INO-4800 in a two-dose regimen (2.0 mg per dose), administered one month apart.
The primary endpoint of this case-driven Phase 3 trial is virologically confirmed symptomatic COVID-19.
Related content: Benzinga's Full FDA Calendar.
Price Action: INO shares are up 3.56% at $6.98 during the market session on the last check Tuesday.